NUVB Q4 2024 Earnings — Nuvation Bio Inc. Revenue & Financial Results | Market Cap Arena

NUVBNuvation Bio Inc.

$2B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M

Gross Profit

$1M26.2% margin

Operating Income

-$54M-944.5% margin

Net Income

-$49M-865.8% margin

EPS (Diluted)

$-0.15

QoQ Revenue Growth

+685.6%

Cash Flow

Operating Cash Flow

-$46M

Free Cash Flow

-$46M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$541M

Total Liabilities

$77M

Stockholders' Equity

$464M

Cash & Equivalents

$36M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$0	—
Gross Profit	$1M	$0	—
Operating Income	-$54M	-$21M	-159.0%
Net Income	-$49M	-$14M	-258.6%

Geographic Segments

CHINA

$5M71%

JAPAN

$2M29%